Polaryx activates first site for pediatric PLX-200 Phase 2 trial

Polaryx Therapeutics says it has activated the first site for SOTERIA, its Phase 2 trial of oral PLX-200 in four rare pediatric disorders. Boys Town National Research Hospital in Nebraska can now begin protocol-directed screening of eligible children. First patient dosing remains a future milestone. The trial will assess safety, tolerability, drug processing in the body and clinical activity in CLN2 disease, CLN3 disease, Krabbe disease and Sandhoff disease. It includes an initial sentinel group for early safety assessment before broader enrollment. The open-label, single-arm study plans six U.S. sites, with the five remaining sites expected to activate by the end of the first quarter of 2027.